Although no clinical therapies directly targeting CYP27A1 currently exist, its regulatory role in the tumor microenvironment suggests its potential value as a predictive biomarker for targeted therapy efficacy in bladder cancer. Here, CYP27A1 is linked to urinary bladder cancer.